Davis Polk advised Zai Lab Limited in connection with its first follow-on offering of $150 million of American Depositary Shares representing 7,500,000 ordinary shares of the company. The ADSs are listed on the NASDAQ Global Market under the symbol “ZLAB.”

Zai Lab is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. The company’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and addressing unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Jennifer Ying Lan, Bria J.M. Cunningham and Sana Bargach. Counsel Alon Gurfinkel and associate Veronica Orecharova provided tax advice. The intellectual property and technology team included partner David R. Bauer and associate Yifu Chen. Counsel Gregory D. Hughes provided executive compensation advice. Associate Huiyu Yin provided 1940 Act advice. Members of the Davis Polk team are based in the New York, London and Northern California offices.

Copy link to share post